January 2026 in “Annals of Clinical Endocrinology and Metabolism” Restoring NAD⁺ may help with aging and chronic diseases, but more research is needed.
January 2026 in “Revista Científica de la Facultad de Ciencias Veterinarias” Ozonated oil and Centella asiatica extract improve wound healing in mice, with each having specific benefits.
January 2026 in “Immune Network” Regulatory T cells adapt to different environments to control inflammation and support tissue repair.
January 2026 in “Archive ouverte UNIGE (University of Geneva)” Skin-sparing techniques in gynecomastia surgery lead to good chest results and high patient satisfaction with less scarring.
December 2025 in “BMC Medical Genomics” Hair follicles can be used to study gene expression and understand conditions like COPD.
December 2025 in “npj Breast Cancer” Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Upadacitinib effectively treats severe alopecia areata and is safe.
October 2025 in “Open Repository of the University of Porto (University of Porto)” Pharmacists play a crucial role in health literacy and patient care.
October 2025 in “Dermatology and Therapy” Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
Steatocystomas are harmless skin cysts that can vary in size and may sometimes cause itching or pain.
September 2025 in “Arthritis Research & Therapy” BMS-470539 reduces skin fibrosis and inflammation.
August 2025 in “International Journal For Multidisciplinary Research” Adaptive coping reduces PCOS symptoms, while maladaptive coping worsens them.
July 2025 in “Scientific Reports” RG and RJ gels speed up burn wound healing better than other treatments.
March 2025 in “SKIN The Journal of Cutaneous Medicine” Certain patient characteristics can help predict hair regrowth success with ritlecitinib in alopecia areata.
March 2025 in “MAEDICA – a Journal of Clinical Medicine” COVID-19 may worsen symptoms of benign prostatic hyperplasia (BPH).
January 2025 in “Frontiers in Immunology” IVIG therapy significantly improved symptoms in a patient with APS-2 and SPS.
January 2025 in “Bright Sky Publications eBooks” Advancements in medical physics and laser technology are improving healthcare but access remains unequal globally.
January 2025 in “International Journal of Advanced Biochemistry Research” Fluralaner effectively cures canine demodicosis in 28 days.
January 2025 in “il Diabete” Targeted drug delivery to pancreatic beta-cells can improve type 2 diabetes treatment.
December 2024 in “Nordisk tidsskrift for helseforskning” People with alopecia areata face challenges but find ways to cope and live fulfilling lives.
November 2024 in “Open Repository of the University of Porto (University of Porto)” Tailored medication preparation and ongoing education are crucial for effective treatments.
October 2024 in “SPIRE - Sciences Po Institutional REpository” Glypicans help hair follicle stem cells differentiate by interacting with specific receptors, influencing hair growth.
July 2024 in “Egyptian Journal of Medical Human Genetics” These gene variations are not linked to alopecia areata in Egyptians.
June 2024 in “Frontiers in pharmacology” 2-deoxy-D-ribose gel may help regrow hair in cases of hair loss.
Attractive women slightly worsened mood, green backgrounds improved mood, and older people had better moods.
April 2024 in “Frontiers in medicine” Alopecia Areata significantly lowers quality of life and current treatments are inadequate, highlighting a need for better therapies and standardized treatment protocols.
April 2024 in “Cell death and differentiation” Cell death shapes skin stem cell environments, affecting inflammation, repair, and cancer.
March 2024 in “Research Square (Research Square)” Scalp cooling therapy helps preserve hair during chemotherapy for most patients.
March 2024 in “Clinical, cosmetic and investigational dermatology” Severe alopecia areata greatly impacts quality of life, mental health, and daily activities.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.